This was the best news this week since the ABBSI P2 results. IPIX needed $ and they got it. IPIX needed product validation from big pharma and they got it. This will bring in new investors who can get in at a very attractive price. And If IPIX needs to access funding, it will be much easier, and on better terms. In short, the deal provided the breathing room they needed to execute on their plan. Looking forward to hearing more from the company about their progress.